Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OCGN 
Ocugen Inc (OCGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: OCGN (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.2
1 Year Target Price $8.2
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 169.02% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 430.98M USD | Price to earnings Ratio - | 1Y Target Price 8.2 |
Price to earnings Ratio - | 1Y Target Price 8.2 | ||
Volume (30-day avg) 4 | Beta 4.51 | 52 Weeks Range 0.52 - 1.90 | Updated Date 11/6/2025 |
52 Weeks Range 0.52 - 1.90 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.06 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) -1004.73% |
Management Effectiveness
Return on Assets (TTM) -73.55% | Return on Equity (TTM) -569.99% |
Valuation
Trailing PE - | Forward PE 15.22 | Enterprise Value 558589382 | Price to Sales(TTM) 80.26 |
Enterprise Value 558589382 | Price to Sales(TTM) 80.26 | ||
Enterprise Value to Revenue 117.5 | Enterprise Value to EBITDA -1.95 | Shares Outstanding 312304736 | Shares Floating 287937703 |
Shares Outstanding 312304736 | Shares Floating 287937703 | ||
Percent Insiders 1.49 | Percent Institutions 16.67 |
Upturn AI SWOT
Ocugen Inc
Company Overview
History and Background
Ocugen Inc. was founded in 2013. Initially focused on developing therapies for eye diseases, it pivoted to developing and commercializing COVAXIN, a COVID-19 vaccine, for the U.S. market.
Core Business Areas
- Vaccines: Focused on the development and commercialization of COVAXIN, a COVID-19 vaccine. This is Ocugen's primary focus area.
- Ophthalmology: Ocugen maintains a pipeline of gene therapies targeting eye diseases, including dry age-related macular degeneration (dAMD), retinitis pigmentosa, and diabetic macular edema.
Leadership and Structure
Dr. Shankar Musunuri is the Chairman, CEO, and Co-Founder. The company operates with a typical biotech organizational structure, involving research, development, clinical, regulatory, and commercial departments.
Top Products and Market Share
Key Offerings
- COVAXIN: A whole-virion inactivated COVID-19 vaccine. While approved for use in some countries (India), it has not received approval or authorization in the US or Canada. Competitors include Pfizer/BioNTech (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ).
- OCU400 (Modifier Gene Therapy Platform): A gene therapy candidate addressing inherited retinal diseases caused by mutations in multiple genes. It has the potential to treat a broad range of genetic eye diseases. Competitors are limited as this is a gene therapy with a novel mechanism.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies developing and marketing new therapies. The vaccine market is dominated by established players. Ophthalmology faces significant unmet needs for effective treatments for various eye diseases.
Positioning
Ocugen is a small biotech company attempting to compete in both the vaccine and ophthalmology markets. Its competitive advantage is linked to COVAXIN's safety profile and its Modifier Gene Therapy Platform's ability to address multiple genetic eye diseases.
Total Addressable Market (TAM)
The global vaccine market is estimated at hundreds of billions of dollars annually. The gene therapy market for eye diseases is estimated in billions and growing. Ocugen aims to capture a share through its vaccine and gene therapy platforms.
Upturn SWOT Analysis
Strengths
- Potential for COVAXIN to address unmet needs in COVID-19 vaccination.
- Novel Modifier Gene Therapy Platform targeting multiple genetic eye diseases.
- Experienced leadership team with expertise in drug development.
Weaknesses
- Lack of regulatory approvals for COVAXIN in key markets (US, Canada).
- Reliance on partnerships for manufacturing and distribution.
- Limited financial resources compared to larger pharmaceutical companies.
- Early stage gene therapy programs.
Opportunities
- Potential for COVAXIN approval in additional countries.
- Expansion of the Modifier Gene Therapy Platform to address other diseases.
- Strategic partnerships with larger pharmaceutical companies.
- Government funding opportunities for vaccine development and gene therapy research.
Threats
- Competition from established vaccine manufacturers.
- Regulatory hurdles for vaccine and gene therapy approvals.
- Clinical trial failures.
- Dependence on regulatory decisions.
- Financial risks and potential for dilution.
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
- VRTX
Competitive Landscape
Ocugen faces intense competition in both the vaccine and ophthalmology markets. Its small size and limited resources present challenges in competing with larger, more established players. Ocugen is focused on a few eye diseases.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by speculative increases in stock price following partnerships and announcements.
Future Projections: Future growth depends heavily on securing regulatory approvals for COVAXIN and progressing its gene therapy pipeline.
Recent Initiatives: Recent initiatives include seeking regulatory approvals for COVAXIN and advancing clinical trials for its Modifier Gene Therapy Platform.
Summary
Ocugen is a high-risk, high-reward biotech company. Its future is heavily reliant on regulatory approvals for COVAXIN and the success of its gene therapy programs. The company's strengths lie in its novel technology, but its weaknesses include financial constraints and competition. Investors should carefully consider these factors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Ocugen Inc. Investor Relations
- Company SEC Filings
- Industry Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and due diligence. Market share figures are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocugen Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2014-12-03 | Co-Founder, CEO & Chairman Dr. Shankar Musunuri M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.ocugen.com |
Full time employees 95 | Website https://www.ocugen.com | ||
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.